معرفی
Dr. Barbara Kemp-Harper is a Senior Lecturer in the Department of Pharmacology at Monash University, where she leads the Vascular Signalling Group within the Vascular Biology and Immunopharmacology Group. She is affiliated with both the Monash Biomedicine Discovery Institute and the Victorian Heart Institute (VHI), contributing to cardiovascular research across these institutions.
Dr. Kemp-Harper is a vascular pharmacologist with extensive expertise in blood vessel function and cardiovascular disease mechanisms. Her research focuses on improving vascular function in conditions including hypertension, high cholesterol, and diabetes. She has gained international recognition for her work on nitroxyl, a novel sibling molecule of nitric oxide, identifying potential therapeutic applications for nitroxyl-like drugs in treating angina, high blood pressure, and high cholesterol.
Her research interests center around vascular pharmacology, with specific focus on nitric oxide signaling pathways, vascular dysfunction in disease states, inflammation mechanisms, and novel therapeutic strategies for cardiovascular conditions. Dr. Kemp-Harper's work has significant implications for understanding and treating cardiovascular complications associated with metabolic disorders.
Dr. Kemp-Harper's publication record demonstrates consistent productivity with 104 research outputs documented, including articles, book chapters, and reviews. Her recent work shows a strong focus on diabetes-related cardiovascular complications, inflammation, and novel signaling pathways in vascular biology.
Scientific Awards
- ASCEPT (Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists) Service Award (2013)
- Monash Biomedicine Discovery Institute 2017 Award for Outstanding Achievement: Innovation in Learning & Teaching (2017)
- Monash University Exceptional Achievement Award (2005)
- Monash University Exceptional Achievement Award (2017)
Dr. Kemp-Harper has been actively involved in research funding, currently holding or having recently completed multiple significant projects. She serves as Primary Chief Investigator on the project "Knocking down the resistance: a new strategy for the treatment of high blood pressure" (2021-2022) and as Chief Investigator on several others including "Decoding monocyte signalling networks" (2020-2021) and "Therapeutic Approaches to Circumvent NO• Resistance in the Type 2 Diabetic Heart and Vasculature" funded by NHMRC (2017-2019).
Dr. Kemp-Harper leads the Vascular Signalling Group at Monash University, which focuses on understanding vascular signaling pathways and identifying new therapeutic targets for cardiovascular diseases. Her team investigates nitric oxide and nitroxyl signaling, vascular dysfunction in metabolic diseases, and novel approaches to improve vascular function in hypertension and diabetes.
